Biotech Values

[lgonber]

Cowen analyst: Schmidt believes the weakness was due to the unsubstantiated possibility of a patient death in the lead-in portion of the Ph I/II trial in DLBCL.

"We believe it likely that such a patient would have died due to circumstances unrelated to therapy (these are very sick patients)," Schmidt commented. "Nonetheless, Kite is "excited" to present data from Ph I at ASH and is on track to start Ph II in H2."